Non-small Cell Lung Cancer Clinical Trials in Beijing
12 recruitingBeijing, China
Showing 1–12 of 12 trials
Recruiting
Phase 3
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled192 locationsNCT07195695
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled300 locationsNCT06692738
Recruiting
Phase 2
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Non-small Cell Lung Cancer
AstraZeneca180 enrolled77 locationsNCT06448754
Recruiting
Phase 1
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Non-small Cell Lung CancerThoracic Tumors
Amgen500 enrolled83 locationsNCT06333951
Recruiting
Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Daiichi Sankyo686 enrolled100 locationsNCT06899126
Recruiting
Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Non-small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Eli Lilly and Company630 enrolled52 locationsNCT06586515
Recruiting
Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
AstraZeneca582 enrolled164 locationsNCT06350097
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Non-small Cell Lung Cancer
Daiichi Sankyo150 enrolled23 locationsNCT06809764
Recruiting
Multiomics Tumor Evolution Model of NSCLC
Non-small Cell Lung Cancer
Peking University People's Hospital300 enrolled1 locationNCT05352035
Recruiting
Phase 2
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
Non-small Cell Lung CancerConsolidation ImmunotherapyRadiotherapy or Sequential Chemoradiation
Peking University Cancer Hospital & Institute20 enrolled1 locationNCT05758116
Recruiting
Phase 2
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Non-small Cell Lung Cancer
Peking Union Medical College Hospital27 enrolled1 locationNCT06388031
Recruiting
Phase 2
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Peking Union Medical College Hospital114 enrolled1 locationNCT05445310